Back to News

DevsHealth announces strategic partnership with Aragen for the chemical synthesis of its projects

It is a key milestone to propel pipeline development and enhances DevsHealth relationship with India, a fast growing country on pharmaceutical industry

DevsHealth is thrilled to announce a landmark agreement with Aragen, a leading company in the synthesis of chemical compounds, headquartered in India and with offices in Europe and North America. This strategic partnership establishes Aragen as DevsHealth’s primary synthesis provider and partner for all chemical synthesis requirements.

As part of this agreement, Aragen has made an in-kind investment in DevsHealth. Aragen will undertake DevsHealth’s synthesis projects as an investment, operating on a success-based payment model. This innovative approach will allow DevsHealth to significantly accelerate its pipeline development. Historically, chemical synthesis has been a bottleneck for DevsHealth, limiting the pace of its advancements.

With Aragen’s expertise and resources, DevsHealth is poised to overcome this hurdle and expedite its research and development activities. DevsHealth employs its own state-of-the-art computational platform to develop new treatments for infectious diseases. This platform, combined with Aragen’s synthesis capabilities, will further boost DevsHealth’s efficiency in bringing novel therapies to market.

This partnership with Aragen marks a key milestone for DevsHealth. Aragen’s investment and collaboration will enable DevsHealth to streamline its synthesis processes and bring its cutting-edge therapies to market more swiftly. DevsHealth is confident that this agreement will greatly enhance its capabilities and contribute to its mission of improving healthcare outcomes through innovation.

Aragen, renowned for its state-of-the-art facilities and extensive experience in chemical synthesis, will leverage its technological prowess to support DevsHealth’s projects. The collaboration is set to foster a dynamic synergy, combining DevsHealth’s innovative research with Aragen’s synthesis expertise, ultimately driving forward the development of transformative therapies.

The success-based payment model underscores the confidence both companies have in the potential of this partnership. By aligning interests and sharing risks, this agreement not only strengthens the commitment between DevsHealth and Aragen but also sets a precedent for future collaborations within the industry.

This agreement enforces the relationship of DevsHealth with India, where the company is already running one of its projects, a broad spectrum treatment for flavivirus infections, together with the Indian Foundation for Neglected Diseases Research. Pharmaceutical industry in India is growing very fast, being the third largest in the world by volume and the major exporter of pharmaceuticals.

Source: DevsHealth